Document Detail


Angiotensin II receptor antagonists.
MedLine Citation:
PMID:  10696996     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Blockade of the renin-angiotensin system began as a way of studying the pathogenesis of cardiovascular disease with specific pharmacological probes. Oral activity, achieved by shortening the original peptide structures, transformed the probes into therapeutic agents, the angiotensin-converting enzyme (ACE) inhibitors. However, ACE is a non-specific target for blocking the renin-angiotensin enzymatic cascade. The availability of orally active drugs turned ACE inhibition into a therapeutic breakthrough but more specific blockade always seemed desirable. This goal has now been achieved with the orally active angiotensin II receptor antagonists; six are on the market and more are under development. This new class of drugs is equal in efficacy to ACE inhibitors, at least in hypertensive patients. Trials now underway will demonstrate whether angiotensin II receptor antagonists can prevent target-organ damage and reduce cardiovascular morbidity and mortality. If they do, these compounds might one day replace ACE inhibitors.
Authors:
M Burnier; H R Brunner
Related Documents :
11403356 - Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angio...
9833176 - Interaction between insulin and at1 receptor. relevance for hypertension and arterioscl...
1290616 - Rationale for the chemical development of angiotensin ii receptor antagonists.
10194466 - Patients with preeclampsia develop agonistic autoantibodies against the angiotensin at1...
2384096 - Rapid turnover of low-density lipoprotein receptor by a non-lysosomal pathway in mouse ...
16585606 - Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in graves'...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Lancet     Volume:  355     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  2000 Feb 
Date Detail:
Created Date:  2000-03-22     Completed Date:  2000-03-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  637-45     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, Centre Hospitalier Universitaire, Lausanne, Switzerland. Michel.Burnier@chuv.hospvd.ch
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Animals
Antihypertensive Agents / therapeutic use*
Clinical Trials as Topic
Dogs
Humans
Hypertension / drug therapy*
Receptors, Angiotensin / antagonists & inhibitors*
Renin-Angiotensin System / drug effects
Safety
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Receptors, Angiotensin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Exposure to airborne dust contaminated with pesticide in the Aral Sea region.
Next Document:  COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease.